Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ: LGND · Real-Time Price · USD

209.52

-1.47 (-0.70%)

At close: Mar 18, 2026, 4:00 PM EDT

209.52

0.00 (0.00%)

After-hours: Mar 18, 2026, 4:10 PM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Development and Licensing of Biopharmaceutical Assets	268.09M	167.13M	131.31M	196.25M	241.54M
Development and Licensing of Biopharmaceutical Assets Growth	60.40%	27.28%	-33.09%	-18.75%	47.68%
Total	268.09M	167.13M	131.31M	196.25M	241.54M
Total Growth	60.40%	27.28%	-33.09%	-18.75%	47.68%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	268.09M	167.13M	131.31M	196.25M	241.54M
United States Growth	60.40%	27.28%	-33.09%	-18.75%	47.68%
Total	268.09M	167.13M	131.31M	196.25M	241.54M
Total Growth	60.40%	27.28%	-33.09%	-18.75%	47.68%

Source: S&P Global Market Intelligence.